Binimetinib

Drug Profile

Binimetinib

Alternative Names: ARRY-162; ARRY-438162; MEK-162; Mitogen activated kinase inhibitor

Latest Information Update: 20 Feb 2017

Price : $50

At a glance

  • Originator Array BioPharma; Dana-Farber Cancer Institute
  • Developer Array BioPharma; German Cancer Research Center; Merck KGaA; Novartis; Pierre Fabre; Seoul National University Hospital; University of Heidelberg
  • Class Amides; Anti-inflammatories; Antineoplastics; Benzimidazoles; Fluorine compounds; Small molecules
  • Mechanism of Action MAP kinase kinase 1 inhibitors; MAP kinase kinase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Malignant melanoma
  • Phase III Colorectal cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Phase II Haematological malignancies; Multiple myeloma; Neurofibromatoses; Non-small cell lung cancer; Solid tumours
  • Phase I/II Acute myeloid leukaemia; Biliary cancer; Chronic myeloid leukaemia; Pancreatic cancer
  • Discontinued Rheumatoid arthritis; Uveal melanoma

Most Recent Events

  • 09 Feb 2017 Phase-II clinical trials in Neurofibromatosis (In children, In adults) in USA (PO)
  • 09 Feb 2017 Array BioPharma announces intention to submit NDA and MAA in 2017
  • 09 Feb 2017 Pharmacodynamics data from preclinical studies in Solid tumour released by Array BioPharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top